PEX11A

Across TCGA pan-cancer cohorts, PEX11A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PEX11A data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PEX11A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PEX11A expression acts as an unfavorable survival marker.

LUAD, PDAC, and GBM are the cancer types where PEX11A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.267	0.795	.001	16	view →
PDAC	DFS	Quartile	III,IV	0.302	0.962	.024	6	view →
GBM	OS	Tertile	All	0.531	0.868	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PEX11A–LUAD (DFS)

Open the LUAD breakdown →